Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

Research analysts at HC Wainwright cut their Q1 2025 EPS estimates for Vanda Pharmaceuticals in a note issued to investors on Tuesday, February 18th. HC Wainwright analyst R. Selvaraju now anticipates ...

Vanda Pharmaceuticals Inc (VNDA) reports strong Fanapt sales growth and strategic initiatives, despite facing increased ...

H.C. Wainwright raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $20 from $18 and keeps a Buy rating on the shares. The firm ...

Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) had its price target upped by HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Tuesday morning,Benzinga reports. HC ...

Kevin Moran; Chief Financial Officer, Senior Vice President, Treasurer; Vanda Pharmaceuticals Inc Mihael Polymeropoulos; Chairman of the Board, President, Chief Executive Officer; Vanda ...

Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin condition. It's the company's second acquisition in just over a year.

Hello, and thank you for standing by. At this time, I would like to welcome you to the Q4 2024 Vanda Pharmaceuticals, Inc. Earnings Conference Call. [Operator Instructions] I would now like to ...

Intercontinental Exchange and RELX are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

M, consensus $284.9M Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and ...